(Q33428940)

26 July 2017

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia (English)

1 reference

26 July 2017

1 reference

1 reference

9

Gautam Borthakur

1 reference

26 July 2017

2

Sarah Cooley

1 reference

26 July 2017

1

David A Rizzieri

1 reference

26 July 2017

Olatoyosi Odenike

3

1 reference

26 July 2017

Lisette Moonan

4

1 reference

26 July 2017

Kay Hoong Chow

5

1 reference

26 July 2017

Kimberley Jackson

6

1 reference

26 July 2017

Xuejing Wang

7

1 reference

26 July 2017

Leslie Brail

8

1 reference

26 July 2017

6 January 2016

1 reference

26 July 2017

1 reference

26 July 2017

57

1 reference

26 July 2017

8

1 reference

26 July 2017

1800-1806

1 reference

GSK-3: tricks of the trade for a multi-tasking kinase

26 July 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122781

GSK3 inhibitors: development and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122781

Illegitimate WNT signaling promotes proliferation of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122781

Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122781

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122781

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122781

Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122781

10.3109/10428194.2015.1122781

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference